{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:02:36Z","timestamp":1787626956847,"version":"build-2736575974"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40266-022-00939-w","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T01:02:41Z","timestamp":1653613361000},"page":"505-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update"],"prefix":"10.1007","volume":"39","author":[{"given":"Steve","family":"MacDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi Samir","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4761-315X","authenticated-orcid":false,"given":"Babak","family":"Tousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"issue":"1","key":"939_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"12","key":"939_CR2","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/gps.4609","volume":"32","author":"AJ Thomas","year":"2017","unstructured":"Thomas AJ, Taylor JP, McKeith I, Bamford C, Burn D, Allan L, et al. Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. Int J Geriatr Psychiatry. 2017;32(12):1280\u20131304.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"7","key":"939_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/pgfar09070","volume":"9","author":"JT O\u2019Brien","year":"2021","unstructured":"O\u2019Brien JT, Taylor J-P, Thomas A, Bamford C, Vale L, Hill S, et al. Improving the diagnosis and management of Lewy body dementia: the DIAMOND-Lewy research programme including pilot cluster RCT. Program Grants Appl Res. 2021;9(7):1\u2013120.","journal-title":"Program Grants Appl Res."},{"issue":"Suppl.6","key":"939_CR4","doi-asserted-by":"publisher","first-page":"e052531","DOI":"10.1002\/alz.052531","volume":"17","author":"J-P Taylor","year":"2021","unstructured":"Taylor J-P, Pillai M. Current management strategies: the DIAMOND-Lewy toolkit. Alzheimer\u2019s Dement [Internet]. 2021;17(Suppl.6):e052531. https:\/\/doi.org\/10.1002\/alz.052531.","journal-title":"Alzheimer\u2019s Dement [Internet]."},{"key":"939_CR5","doi-asserted-by":"crossref","unstructured":"Vann Jones SA, O\u2019Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med [Internet]. 2014;44(4):673\u201383. https:\/\/pubmed.ncbi.nlm.nih.gov\/23521899\/. [cited 2021 Nov 14].","DOI":"10.1017\/S0033291713000494"},{"key":"939_CR6","doi-asserted-by":"crossref","unstructured":"Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson\u2019s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol [Internet]. 1998;57(4):334\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/9600226\/. [cited 2021 Nov 14].","DOI":"10.1097\/00005072-199804000-00005"},{"key":"939_CR7","doi-asserted-by":"crossref","unstructured":"Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol [Internet]. 2008;115(4):427\u201336. https:\/\/pubmed.ncbi.nlm.nih.gov\/18273624\/. [cited 2021 Nov 14].","DOI":"10.1007\/s00401-008-0347-5"},{"key":"939_CR8","doi-asserted-by":"crossref","unstructured":"Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer\u2019s disease. Neuroreport [Internet]. 1994;5(7):747\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/8018843\/. [cited 2021 Nov 14].","DOI":"10.1097\/00001756-199403000-00002"},{"key":"939_CR9","doi-asserted-by":"crossref","unstructured":"Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer\u2019s and Parkinson\u2019s diseases: rostrocaudal distribution. Brain [Internet]. 1999;122 (Pt 8)(8):1449\u201368. https:\/\/pubmed.ncbi.nlm.nih.gov\/10430831\/. [cited 2021 Nov 14].","DOI":"10.1093\/brain\/122.8.1449"},{"key":"939_CR10","doi-asserted-by":"crossref","unstructured":"Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology [Internet]. 2007;68(11):812\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/17353469\/. [cited 2021 Nov 14].","DOI":"10.1212\/01.wnl.0000256715.13907.d3"},{"key":"939_CR11","doi-asserted-by":"crossref","unstructured":"Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, et al. CSF amyloid-\u03b2 peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer\u2019s disease. J Alzheimers Dis [Internet]. 2011;24(2):383\u201391. https:\/\/pubmed.ncbi.nlm.nih.gov\/21297274\/. [cited 2021 Nov 14].","DOI":"10.3233\/JAD-2011-101551"},{"key":"939_CR12","doi-asserted-by":"crossref","unstructured":"Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D\u2019Amore C, et al. Cerebrospinal fluid biomarkers in Parkinson\u2019s disease with dementia and dementia with Lewy bodies. Biol Psychiatry [Internet]. 2008;64(10):850\u20135. https:\/\/pubmed.ncbi.nlm.nih.gov\/18395699\/. [cited 2021 Nov 14].","DOI":"10.1016\/j.biopsych.2008.02.016"},{"key":"939_CR13","doi-asserted-by":"crossref","unstructured":"McKeith I, O\u2019Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol [Internet]. 2007;6(4):305\u201313. https:\/\/pubmed.ncbi.nlm.nih.gov\/17362834\/. [cited 2021 Nov 14].","DOI":"10.1016\/S1474-4422(07)70057-1"},{"key":"939_CR14","doi-asserted-by":"crossref","unstructured":"Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med [Internet]. 2013;14(8):754\u201362. https:\/\/pubmed.ncbi.nlm.nih.gov\/23474058\/. [cited 2021 Nov 14].","DOI":"10.1016\/j.sleep.2012.10.015"},{"key":"939_CR15","doi-asserted-by":"crossref","unstructured":"Yoshita M, Arai H, Arai H, Arai T, Asada T, Fujishiro H, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One [Internet]. 2015;10(3). https:\/\/pubmed.ncbi.nlm.nih.gov\/25793585\/. [cited 2021 Nov 14].","DOI":"10.1371\/journal.pone.0120540"},{"key":"939_CR16","doi-asserted-by":"crossref","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord [Internet]. 2015;30(12):1591\u2013601. https:\/\/pubmed.ncbi.nlm.nih.gov\/26474316\/. [cited 2021 Nov 14].","DOI":"10.1002\/mds.26424"},{"key":"939_CR17","doi-asserted-by":"crossref","unstructured":"Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol [Internet]. 2017;13(4):217\u201331. https:\/\/pubmed.ncbi.nlm.nih.gov\/28257128\/. [cited 2021 Nov 14].","DOI":"10.1038\/nrneurol.2017.27"},{"key":"939_CR18","doi-asserted-by":"crossref","unstructured":"Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson\u2019s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord [Internet]. 2005;20(2):190\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/15551331\/. [cited 2021 Nov 14].","DOI":"10.1002\/mds.20324"},{"key":"939_CR19","doi-asserted-by":"crossref","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord [Internet]. 2007;22(12):1689\u2013707. https:\/\/pubmed.ncbi.nlm.nih.gov\/17542011\/. [cited 2021 Nov 14].","DOI":"10.1002\/mds.21507"},{"key":"939_CR20","doi-asserted-by":"crossref","unstructured":"Bradshaw J, Saling M, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer\u2019s disease is qualitatively distinct. J Neurol Neurosurg Psychiatry [Internet]. 2004;75(3):382\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/14966152\/. [cited 2021 Nov 14].","DOI":"10.1136\/jnnp.2002.002576"},{"key":"939_CR21","doi-asserted-by":"crossref","unstructured":"Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O\u2019Brien JT, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer\u2019s disease, and vascular dementia. Neurology [Internet]. 2000;54(8):1616\u201324. https:\/\/pubmed.ncbi.nlm.nih.gov\/10762503\/. [cited 2021 Nov 14].","DOI":"10.1212\/WNL.54.8.1616"},{"key":"939_CR22","doi-asserted-by":"crossref","unstructured":"Grothe MJ, Schuster C, Bauer F, Prudlo J, Teipel SJ, Heinsen H. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer\u2019s disease dementia. J Neurol [Internet]. 2014;261(10):1939\u201348. https:\/\/pubmed.ncbi.nlm.nih.gov\/25059393\/. [cited 2021 Nov 14].","DOI":"10.1007\/s00415-014-7439-z"},{"issue":"9247","key":"939_CR23","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"I McKeith","year":"2000","unstructured":"McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031\u20136.","journal-title":"Lancet"},{"key":"939_CR24","doi-asserted-by":"crossref","unstructured":"Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol [Internet]. 2012;72(1):41\u201352. https:\/\/pubmed.ncbi.nlm.nih.gov\/22829268\/. [cited 2021 Nov 14].","DOI":"10.1002\/ana.23557"},{"issue":"1","key":"939_CR25","doi-asserted-by":"publisher","first-page":"4-014-0083-0","DOI":"10.1186\/s13195-014-0083-0","volume":"7","author":"M Ikeda","year":"2015","unstructured":"Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7(1):4-014-0083\u20130 (eCollection 2015).","journal-title":"Alzheimers Res Ther."},{"key":"939_CR26","doi-asserted-by":"crossref","unstructured":"Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord [Internet]. 2007;23(6):401\u20135. https:\/\/pubmed.ncbi.nlm.nih.gov\/17409748\/. [cited 2021 Nov 14].","DOI":"10.1159\/000101512"},{"key":"939_CR27","doi-asserted-by":"crossref","unstructured":"Warre R, Thiele S, Talwar S, Kamal M, Johnston TH, Wang S, et al. Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiol Dis [Internet]. 2011;41(3):591\u2013604. https:\/\/pubmed.ncbi.nlm.nih.gov\/20971190\/. [cited 2021 Nov 14].","DOI":"10.1016\/j.nbd.2010.10.013"},{"key":"939_CR28","doi-asserted-by":"crossref","unstructured":"Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol [Internet]. 2009;8(7):613\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/19520613\/. [cited 2021 Nov 14].","DOI":"10.1016\/S1474-4422(09)70146-2"},{"issue":"10","key":"939_CR29","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969\u201377.","journal-title":"Lancet Neurol"},{"key":"939_CR30","unstructured":"EIP. EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer\u2019s Disease (CTAD) Meeting [Internet accessed 2021 Nov 14]. 2020. https:\/\/www.eippharma.com\/news\/eip-pharma-announces-presentation-of-positive-clinical-trial-results-with-neflamapimod-at-the-13th-clinical-trials-in-alzheimers-disease-ctad-meeting\/."},{"issue":"4","key":"939_CR31","first-page":"S9","volume":"8","author":"J Alam","year":"2021","unstructured":"Alam J, EIP Pharma Boston M. Clinical results with Novel Approaches that Reverses BFCN Dysfunction. J Prev Alzhiemer\u2019s Dis. 2021;8(4):S9.","journal-title":"J Prev Alzhiemer\u2019s Dis."},{"key":"939_CR32","doi-asserted-by":"crossref","unstructured":"Aarsland D, Ballard C, McKeith I, Perry RH, Larsen JP. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci [Internet]. 2001;13(3):374\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/11514644\/. [cited 2021 Nov 14].","DOI":"10.1176\/jnp.13.3.374"},{"issue":"6","key":"939_CR33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1177\/0269881106068299","volume":"20","author":"A Burns","year":"2006","unstructured":"Burns A, O\u2019Brien J, Group BAPDC, Auriacombe S, Ballard C, Broich K, et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006;20(6):732\u201355.","journal-title":"J Psychopharmacol"},{"key":"939_CR34","doi-asserted-by":"crossref","unstructured":"Burn DJ, Rowan EN, Minett T, Sanders J, Myint P, Richardson J, et al. Extrapyramidal features in Parkinson\u2019s disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord [Internet]. 2003;18(8):884\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/12889077\/. [cited 2021 Nov 14].","DOI":"10.1002\/mds.10455"},{"key":"939_CR35","doi-asserted-by":"crossref","unstructured":"Molloy S, McKeith IG, O\u2019Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry [Internet]. 2005;76(9):1200\u20133. https:\/\/pubmed.ncbi.nlm.nih.gov\/16107351\/. [cited 2021 Nov 14].","DOI":"10.1136\/jnnp.2004.052332"},{"key":"939_CR36","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/mds.22322","volume":"23","author":"JG Goldman","year":"2008","unstructured":"Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23(15):2248\u201350.","journal-title":"Mov Disord"},{"key":"939_CR37","unstructured":"Sumitomo Dainippon Pharma Co. Sumitomo Dainippon Pharma Obtains Approval in Japan for TRERIEF, a therapeutic agent for Parkinson\u2019s disease, for an Additional Indication of Parkinsonism in Dementia with Lewy Bodies [Internet]. 2018. https:\/\/www.ds-pharma.com\/ir\/news\/2018\/20180702.html. Accessed 4 Dec 2021."},{"key":"939_CR38","doi-asserted-by":"crossref","unstructured":"Murata M, Hasegawa K, Kanazawa I, Shirakura K, Kochi K, Shimazu R. Randomized placebo-controlled trial of zonisamide in patients with Parkinson\u2019s disease. Neurol Clin Neurosci. 2016;4(1):10\u201315.","DOI":"10.1111\/ncn3.12026"},{"key":"939_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.parkreldis.2019.12.005","volume":"76","author":"M Murata","year":"2020","unstructured":"Murata M, Odawara T, Hasegawa K, Kajiwara R, Takeuchi H, Tagawa M, et al. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: a phase 3 randomized clinical trial. Park Relat Disord. 2020;76:91\u201397.","journal-title":"Park Relat Disord."},{"key":"939_CR40","unstructured":"Dainippon Sumitomo Pharma Co. Parkinson\u2019s disease drug \u201cTRERIEF\u201d obtained manufacturing and marketing approval [Internet]. 2009. https:\/\/www.ds-pharma.com\/ir\/news\/2009\/20090121.html."},{"key":"939_CR41","doi-asserted-by":"crossref","unstructured":"Seino M. Review of zonisamide development in Japan. Seizure. 2004.","DOI":"10.1016\/j.seizure.2004.04.015"},{"key":"939_CR42","doi-asserted-by":"crossref","unstructured":"Tousi B, Leverenz JB. The application of zonisamide to patients suffering from dementia with Lewy bodies: emerging clinical data. Drug Des Devel Ther. 2021;15:1811\u201317.","DOI":"10.2147\/DDDT.S240865"},{"key":"939_CR43","doi-asserted-by":"crossref","unstructured":"Shulman LM, Katzel LI, Ivey FM, Sorkin JD, Favors K, Anderson KE, et al. Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. JAMA Neurol [Internet]. 2013;70(2):183\u201390. https:\/\/pubmed.ncbi.nlm.nih.gov\/23128427\/. [cited 2021 Nov 14].","DOI":"10.1001\/jamaneurol.2013.646"},{"key":"939_CR44","doi-asserted-by":"crossref","unstructured":"Uc EY, Doerschug KC, Magnotta V, Dawson JD, Thomsen TR, Kline JN, et al. Phase I\/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology [Internet]. 2014;83(5):413\u201325. https:\/\/pubmed.ncbi.nlm.nih.gov\/24991037\/. [cited 2021 Nov 14].","DOI":"10.1212\/WNL.0000000000000644"},{"key":"939_CR45","doi-asserted-by":"crossref","unstructured":"Song R, Grabowska W, Park M, Osypiuk K, Vergara-Diaz GP, Bonato P, et al. The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord [Internet]. 2017;41:3\u201313. https:\/\/pubmed.ncbi.nlm.nih.gov\/28602515\/. [cited 2021 Nov 14].","DOI":"10.1016\/j.parkreldis.2017.05.019"},{"key":"939_CR46","doi-asserted-by":"crossref","unstructured":"Ballard C, Holmes C, McKeith I, Neill D, O\u2019Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer\u2019s disease. Am J Psychiatry [Internet]. 1999;156(7):1039\u201345. https:\/\/pubmed.ncbi.nlm.nih.gov\/10401449\/. [cited 2021 Nov 14].","DOI":"10.1176\/ajp.156.7.1039"},{"issue":"1","key":"939_CR47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/geront\/gnq055","volume":"51","author":"AN Leggett","year":"2011","unstructured":"Leggett AN, Zarit S, Taylor A, Galvin JE. Stress and burden among caregivers of patients with Lewy body dementia. Gerontologist. 2011;51(1):76\u201385.","journal-title":"Gerontologist"},{"key":"939_CR48","doi-asserted-by":"crossref","unstructured":"Jellinger KA. Dementia with Lewy bodies and Parkinson\u2019s disease-dementia: current concepts and controversies. J Neural Transm [Internet]. 2018;125(4):615\u201350. https:\/\/pubmed.ncbi.nlm.nih.gov\/29222591\/. [cited 2021 Nov 14].","DOI":"10.1007\/s00702-017-1821-9"},{"key":"939_CR49","doi-asserted-by":"crossref","unstructured":"Ballard CG, O\u2019Brien JT, Swann AG, Thompson P, Neill D, McKeith IG. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer\u2019s disease: persistence and new cases over 1 year of follow-up. J Clin Psychiatry [Internet]. 2001;62(1):46\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/11235928\/. [cited 2021 Nov 14].","DOI":"10.4088\/JCP.v62n0110"},{"issue":"Pt 3","key":"939_CR50","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/brain\/awm322","volume":"131","author":"L Bonanni","year":"2008","unstructured":"Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer\u2019s disease, dementia with Lewy bodies and Parkinson\u2019s disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690\u2013705.","journal-title":"Brain"},{"issue":"1","key":"939_CR51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.archger.2007.03.003","volume":"46","author":"B Borroni","year":"2008","unstructured":"Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr. 2008;46(1):101\u20136.","journal-title":"Arch Gerontol Geriatr"},{"key":"939_CR52","doi-asserted-by":"crossref","unstructured":"Chiu PY, Wang CW, Tsai CT, Li SH, Lin CL, Lai TJ. Depression in dementia with Lewy bodies: A comparison with Alzheimer\u2019s disease. PLoS One [Internet]. 2017;12(6). https:\/\/pubmed.ncbi.nlm.nih.gov\/28617831\/. [cited 2021 Nov 14].","DOI":"10.1371\/journal.pone.0179399"},{"key":"939_CR53","unstructured":"Aarsland D, Perry R, Larsen JP, McKeith IG, O\u2019Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson\u2019s disease and parkinsonian dementias. J Clin Psychiatry [Internet]. 2005;66(5):633\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/15889951\/. [cited 2021 Nov 14]."},{"issue":"3","key":"939_CR54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0278-5846(03)00040-X","volume":"27","author":"H Takahashi","year":"2003","unstructured":"Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(3):549\u201353.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"17","key":"939_CR55","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","volume":"68","author":"R Kurlan","year":"2007","unstructured":"Kurlan R, Cummings J, Raman R, Thal L, Group ADCS. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356\u201363.","journal-title":"Neurology"},{"key":"939_CR56","doi-asserted-by":"crossref","unstructured":"Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord [Internet]. 2002];13(2):67\u201373. https:\/\/pubmed.ncbi.nlm.nih.gov\/11844887\/. [cited 2021 Nov 14.","DOI":"10.1159\/000048636"},{"key":"939_CR57","doi-asserted-by":"crossref","unstructured":"Pollak P, Tison F, Rascol O, Dest\u00e9e A, P\u00e9r\u00e9 JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry [Internet]. 2004;75(5):689\u201395. https:\/\/pubmed.ncbi.nlm.nih.gov\/15090561\/. [cited 2021 Nov 14].","DOI":"10.1136\/jnnp.2003.029868"},{"issue":"1","key":"939_CR58","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103\u201311.","journal-title":"Intern Emerg Med"},{"key":"939_CR59","doi-asserted-by":"crossref","unstructured":"Chu CS, Yang FC, Tseng PT, Stubbs B, Dag A, Carvalho AF, et al. Treatment efficacy and acceptabilityof pharmacotherapies for dementia with Lewy bodies: a systematic review and network meta-analysis. Arch Gerontol Geriatr [Internet]. 2021;96. https:\/\/pubmed.ncbi.nlm.nih.gov\/34256210\/. [cited 2021 Nov 14].","DOI":"10.1016\/j.archger.2021.104474"},{"issue":"9916","key":"939_CR60","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2014;383(9916):533\u201340.","journal-title":"Lancet (London, England)."},{"key":"939_CR61","doi-asserted-by":"crossref","unstructured":"Tariot PN, Cummings JL, Soto-Martin ME, Ballard C, Erten-Lyons D, Sultzer DL, et al. Trial of pimavanserin in dementia-related psychosis. N Engl J Med [Internet]. 2021];385(4):309\u201319. https:\/\/pubmed.ncbi.nlm.nih.gov\/34289275\/. [cited 2021 Nov 14.","DOI":"10.1056\/NEJMoa2034634"},{"key":"939_CR62","unstructured":"Acadia Pharmaceuticals Receives Complete Response Letter from US FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis | Acadia Pharmaceuticals Inc. [Internet]. [Accessed 2021 Nov 14]. https:\/\/ir.acadia-pharm.com\/news-releases\/news-release-details\/acadia-pharmaceuticals-receives-complete-response-letter-us-fda."},{"issue":"3","key":"939_CR63","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3233\/JAD-150818","volume":"50","author":"I Yasue","year":"2016","unstructured":"Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata N. Serotonin 2A receptor inverse agonist as a treatment for Parkinson\u2019s disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimer\u2019s Dis. 2016;50(3):733\u201340.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"939_CR64","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.parkreldis.2019.11.009","volume":"69","author":"S Horn","year":"2019","unstructured":"Horn S, Richardson H, Xie SX, Weintraub D, Dahodwala N. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson\u2019s disease and dementia with Lewy bodies. Park Relat Disord. 2019;69:119\u201324.","journal-title":"Park Relat Disord."},{"key":"939_CR65","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","volume":"19","author":"JP Taylor","year":"2020","unstructured":"Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19:157\u201369.","journal-title":"Lancet Neurol"},{"key":"939_CR66","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review. Mov Disord. 2019;34:180\u201398.","journal-title":"Mov Disord"},{"key":"939_CR67","doi-asserted-by":"crossref","unstructured":"Culo S, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord [Internet]. 2010;24(4):360\u20134. https:\/\/pubmed.ncbi.nlm.nih.gov\/20625270\/. [cited 2021 Nov 14].","DOI":"10.1097\/WAD.0b013e3181e6a4d7"},{"key":"939_CR68","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1113\/JP271324","volume":"594","author":"E Arrigoni","year":"2016","unstructured":"Arrigoni E, Chen MC, Fuller PM. The anatomical, cellular and synaptic basis of motor atonia during rapid eye movement sleep. J Physiol. 2016;594:5391\u2013414.","journal-title":"J Physiol"},{"issue":"2","key":"939_CR69","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jalz.2012.03.003","volume":"9","author":"AL Boxer","year":"2013","unstructured":"Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013;9(2):189\u201398.","journal-title":"Alzheimers Dement"},{"key":"939_CR70","doi-asserted-by":"crossref","unstructured":"Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology [Internet]. 2009;72(15):1296\u2013300. https:\/\/pubmed.ncbi.nlm.nih.gov\/19109537\/. [cited 2021 Nov 14].","DOI":"10.1212\/01.wnl.0000340980.19702.6e"},{"key":"939_CR71","doi-asserted-by":"crossref","unstructured":"Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med [Internet]. 2013;14(8):744\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/23347909\/. [cited 2021 Nov 14].","DOI":"10.1016\/j.sleep.2012.10.009"},{"key":"939_CR72","doi-asserted-by":"crossref","unstructured":"Neikrug AB, Ancoli-Israel S. Diagnostic tools for REM sleep behavior disorder. Sleep Med Rev [Internet]. 2012;16(5):415\u201329. https:\/\/pubmed.ncbi.nlm.nih.gov\/22169258\/. [cited 2021 Nov 14].","DOI":"10.1016\/j.smrv.2011.08.004"},{"issue":"5","key":"939_CR73","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jamaneurol.2014.65","volume":"71","author":"DP Breen","year":"2014","unstructured":"Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, et al. Sleep and circadian rhythm regulation in early parkinson disease. JAMA Neurol. 2014;71(5):589\u201395.","journal-title":"JAMA Neurol"},{"key":"939_CR74","doi-asserted-by":"crossref","unstructured":"McCarter SJ, Boswell CL, St. Louis EK, Dueffert LG, Slocumb N, Boeve BF, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med [Internet]. 2013;14(3):237\u201342. https:\/\/pubmed.ncbi.nlm.nih.gov\/23352028\/. [cited 2021 Nov 14].","DOI":"10.1016\/j.sleep.2012.09.018"},{"issue":"1","key":"939_CR75","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.sleep.2014.09.011","volume":"16","author":"IR McGrane","year":"2015","unstructured":"McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015;16(1):19\u201326.","journal-title":"Sleep Med"},{"key":"939_CR76","doi-asserted-by":"crossref","unstructured":"Schenck CH, Mahowald MW. Polysomnographie, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RBD): sustained clonazepam efficacy in 89.5% of 57 treated patients. Cleve Clin J Med [Internet]. 1990;57(1 suppl 1):S-9. https:\/\/www.ccjm.org\/content\/57\/1_suppl_1\/S-9. [cited 2021 Nov 14].","DOI":"10.3949\/ccjm.57.s1.9"},{"key":"939_CR77","doi-asserted-by":"crossref","unstructured":"Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain [Internet]. 2000;123 (Pt 2)(2):331\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/10648440\/. [cited 2021 Nov 14].","DOI":"10.1093\/brain\/123.2.331"},{"key":"939_CR78","doi-asserted-by":"crossref","unstructured":"Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med [Internet]. 1996;100(3):333\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/8629680\/. [cited 2021 Nov 14].","DOI":"10.1016\/S0002-9343(97)89493-4"},{"key":"939_CR79","doi-asserted-by":"crossref","unstructured":"Di Giacopo R, Fasano A, Quaranta D, Marca G Della, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson\u2019s disease. Mov Disord [Internet]. 2012;27(4):559\u201361. https:\/\/pubmed.ncbi.nlm.nih.gov\/22290743\/. [cited 2021 Nov 14].","DOI":"10.1002\/mds.24909"},{"key":"939_CR80","doi-asserted-by":"crossref","unstructured":"Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology [Internet]. 2000;55(6):870\u20131. https:\/\/pubmed.ncbi.nlm.nih.gov\/10994012\/. [cited 2021 Nov 14].","DOI":"10.1212\/WNL.55.6.870"},{"key":"939_CR81","doi-asserted-by":"crossref","unstructured":"Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology [Internet]. 2006;67(5):742\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/16966533\/. [cited 2021 Nov 14].","DOI":"10.1212\/01.wnl.0000233926.47469.73"},{"key":"939_CR82","doi-asserted-by":"crossref","unstructured":"Mendoza-Vel\u00e1squez JJ, Flores-V\u00e1zquez JF, Barr\u00f3n-Vel\u00e1zquez E, Sosa-Ortiz AL, Illigens BMW, Siepmann T. Autonomic Dysfunction in \u03b1-Synucleinopathies. Front Neurol [Internet]. 2019;10(APR). https:\/\/pubmed.ncbi.nlm.nih.gov\/31031694\/. [cited 2021 Nov 14].","DOI":"10.3389\/fneur.2019.00363"},{"key":"939_CR83","doi-asserted-by":"crossref","unstructured":"Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol [Internet]. 2013;9(1):13\u201324. https:\/\/pubmed.ncbi.nlm.nih.gov\/23183883\/. [cited 2021 Nov 14].","DOI":"10.1038\/nrneurol.2012.242"},{"key":"939_CR84","doi-asserted-by":"crossref","unstructured":"Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer\u2019s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry [Internet]. 2001;71(5):583\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/11606666\/. [cited 2021 Nov 14].","DOI":"10.1136\/jnnp.71.5.583"},{"key":"939_CR85","doi-asserted-by":"crossref","unstructured":"Joseph A, Wanono R, Flamant M, Vidal-Petiot E. Orthostatic hypotension: a review. Nephrol Ther [Internet]. 2017;13 Suppl 1:S55\u201367. https:\/\/pubmed.ncbi.nlm.nih.gov\/28577744\/. [cited 2021 Nov 14].","DOI":"10.1016\/j.nephro.2017.01.003"},{"key":"939_CR86","doi-asserted-by":"crossref","unstructured":"Horimoto Y, Matsumoto M, Akatsu H, Ikari H, Kojima K, Yamamoto T, et al. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol [Internet]. 2003;250(5):530\u20133. https:\/\/pubmed.ncbi.nlm.nih.gov\/12736730\/. [cited 2021 Nov 14].","DOI":"10.1007\/s00415-003-1029-9"},{"key":"939_CR87","doi-asserted-by":"crossref","unstructured":"Bengtsson-Lindberg M, Larsson V, Minthon L, Wattmo C, Londos E. Lack of orthostatic symptoms in dementia patients with orthostatic hypotension. Clin Auton Res [Internet]. 2015;25(2):87\u201394. https:\/\/pubmed.ncbi.nlm.nih.gov\/24743866\/. [cited 2021 Nov 14].","DOI":"10.1007\/s10286-014-0244-z"},{"key":"939_CR88","doi-asserted-by":"crossref","unstructured":"Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord [Internet]. 2018;33(3):372\u201390. https:\/\/pubmed.ncbi.nlm.nih.gov\/29508455\/. [cited 2021 Nov 14].","DOI":"10.1002\/mds.27344"},{"key":"939_CR89","doi-asserted-by":"crossref","unstructured":"Tateno F, Sakakibara R, Ogata T, Kishi M, Tsuyusaki Y, Takahashi O, et al. Lower urinary tract function in dementia with Lewy bodies (DLB). Mov Disord [Internet]. 2015;30(3):411\u20135. https:\/\/pubmed.ncbi.nlm.nih.gov\/25356960\/. [cited 2021 Nov 14].","DOI":"10.1002\/mds.25985"},{"key":"939_CR90","doi-asserted-by":"crossref","unstructured":"Peyronnet B, Vurture G, Palma JA, Malacarne DR, Feigin A, Sussman RD, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord [Internet]. 2018;57:22\u20136. https:\/\/pubmed.ncbi.nlm.nih.gov\/30037689\/. [cited 2021 Nov 14].","DOI":"10.1016\/j.parkreldis.2018.07.005"},{"key":"939_CR91","doi-asserted-by":"crossref","unstructured":"Kalf JG, De Swart BJM, Borm GF, Bloem BR, Munneke M. Prevalence and definition of drooling in Parkinson\u2019s disease: a systematic review. J Neurol [Internet]. 2009;256(9):1391\u20136. https:\/\/pubmed.ncbi.nlm.nih.gov\/19288042\/. [cited 2021 Nov 14].","DOI":"10.1007\/s00415-009-5098-2"},{"key":"939_CR92","doi-asserted-by":"crossref","unstructured":"Arbouw MEL, Movig KLL, Koopmann M, Poels PJE, Guchelaar HJ, Egberts TCG, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology [Internet]. 2010;74(15):1203\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/20385892\/. [cited 2021 Nov 14].","DOI":"10.1212\/WNL.0b013e3181d8c1b7"},{"key":"939_CR93","doi-asserted-by":"crossref","unstructured":"Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord [Internet]. 2011;26 Suppl 3(0 3). https:\/\/pubmed.ncbi.nlm.nih.gov\/22021174\/. [cited 2021 Nov 14].","DOI":"10.1002\/mds.23884"},{"key":"939_CR94","doi-asserted-by":"crossref","unstructured":"Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, et al. Assessing the non-motor symptoms of Parkinson\u2019s disease: MDS-UPDRS and NMS Scale. Eur J Neurol [Internet]. 2015;22(1):37\u201343. https:\/\/pubmed.ncbi.nlm.nih.gov\/23607783\/. [cited 2021 Nov 14].","DOI":"10.1111\/ene.12165"},{"key":"939_CR95","doi-asserted-by":"crossref","unstructured":"Stubendorff K, Aarsland D, Minthon L, Londos E. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson\u2019s disease with dementia. PLoS One [Internet]. 2012;7(10). https:\/\/pubmed.ncbi.nlm.nih.gov\/23049679\/. [cited 2021 Nov 14].","DOI":"10.1371\/journal.pone.0045451"},{"key":"939_CR96","doi-asserted-by":"crossref","unstructured":"Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EMM. Constipation in Parkinson\u2019s disease: objective assessment and response to psyllium. Mov Disord [Internet]. 1997;12(6):946\u201351. https:\/\/pubmed.ncbi.nlm.nih.gov\/9399219\/. [cited 2021 Nov 14].","DOI":"10.1002\/mds.870120617"},{"key":"939_CR97","doi-asserted-by":"crossref","unstructured":"Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, et al. Macrogol for the treatment of constipation in Parkinson\u2019s disease. A randomized placebo-controlled study. Mov Disord [Internet]. 2007;22(9):1239\u201344. https:\/\/pubmed.ncbi.nlm.nih.gov\/17566120\/. [cited 2021 Nov 14].","DOI":"10.1002\/mds.21243"},{"issue":"12","key":"939_CR98","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/WNL.0000000000003127","volume":"87","author":"M Barichella","year":"2016","unstructured":"Barichella M, Pacchetti C, Bolliri C, Cassani E, Iorio L, Pusani C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease. Neurology. 2016;87(12):1274\u201380.","journal-title":"Neurology"},{"issue":"2","key":"939_CR99","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/mdc3.12577","volume":"5","author":"ME Freitas","year":"2018","unstructured":"Freitas ME, Alqaraawi A, Lang AE, Liu LWC. Linaclotide and prucalopride for management of constipation in patients with parkinsonism. Mov Disord Clin Pract. 2018;5(2):218\u201320.","journal-title":"Mov Disord Clin Pract."},{"key":"939_CR100","unstructured":"Eisai. ARICEPT\u00ae approved in japan as treatment for dementia with Lewy bodies [Internet]. 2014. https:\/\/www.eisai.com\/news\/news201452.html. [cited 2022 Mar 30]."},{"key":"939_CR101","doi-asserted-by":"crossref","unstructured":"Lang FM, Kwon DY, Aarsland D, Boeve B, Tousi B, Harnett M, et al. An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). Alzheimers Dement (N Y). 2021;7(1):e12171.","DOI":"10.1002\/trc2.12171"},{"key":"939_CR102","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.4103\/1673-5374.165320","volume":"10","author":"M Hebron","year":"2015","unstructured":"Hebron M, Moussa CEH. Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration. Neural Regener Res. 2015;10:1767\u20139.","journal-title":"Neural Regener Res."},{"issue":"16","key":"939_CR103","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","volume":"22","author":"ML Hebron","year":"2013","unstructured":"Hebron ML, Lonskaya I, Moussa CEH. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson\u2019s disease models. Hum Mol Genet. 2013;22(16):3315\u201328.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"939_CR104","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/hmg\/ddt674","volume":"23","author":"AL Mahul-Mellier","year":"2014","unstructured":"Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, et al. C-Abl phosphorylates \u03b1-synuclein and regulates its degradation: Implication for \u03b1-synuclein clearance and contribution to the pathogenesis of Parkinson\u2019s disease. Hum Mol Genet. 2014;23(11):2858\u201379.","journal-title":"Hum Mol Genet"},{"key":"939_CR105","unstructured":"Merchant K, Simuni T, Fiske B, Coffey C, Matthews H, Wyse R, et al. Pharmacokinetics and biomarker changes in NILO-PD, a phase 2A study of nilotinib in patients with moderate to advance Parkinson\u2019s disease (4418). Neurology. 2020;94(15 Supplement)."},{"issue":"1","key":"939_CR106","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.25775","volume":"88","author":"RS Turner","year":"2020","unstructured":"Turner RS, Hebron ML, Lawler A, Mundel EE, Yusuf N, Starr JN, et al. Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer\u2019s disease. Ann Neurol. 2020;88(1):183\u201394.","journal-title":"Ann Neurol"},{"key":"939_CR107","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.neuroscience.2015.07.070","volume":"304","author":"I Lonskaya","year":"2015","unstructured":"Lonskaya I, Hebron ML, Selby ST, Turner RS, Moussa CEH. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer\u2019s disease models. Neuroscience. 2015;304:316\u201327.","journal-title":"Neuroscience"},{"issue":"3","key":"939_CR108","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1212\/CPJ.0000000000000918","volume":"11","author":"K Mahdavi","year":"2021","unstructured":"Mahdavi K, Jordan S, Barrows H, Pravdic M, Habelhah B, Evans N, et al. Treatment of dementia with bosutinib: an open-label study of a tyrosine kinase inhibitor. Neurol Clin Pract. 2021;11(3):e294\u2013e302.","journal-title":"Neurol Clin Pract."},{"key":"939_CR109","doi-asserted-by":"crossref","unstructured":"Ando M, Ishikawa Y, Horie K, Mochizuki T, Yamamoto M, Watanabe N, et al. P3\u2010062: effect of repeated administration of E2027, a novel phosphodiesterase\u20109 inhibitor, on cyclic GMP levels in rat cerebrospinal fluid. Alzheimer\u2019s Dement. 2018;14(7S_Part_20).","DOI":"10.1016\/j.jalz.2018.06.1418"},{"key":"939_CR110","doi-asserted-by":"crossref","unstructured":"H\u00f6llerhage M, Moebius C, Melms J, Chiu WH, Goebel JN, Chakroun T, et al. Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Sci Rep. 2017;7(1):11469.","DOI":"10.1038\/s41598-017-11664-5"},{"issue":"10","key":"939_CR111","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1172\/JCI129987","volume":"129","author":"R Cai","year":"2019","unstructured":"Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, et al. Enhancing glycolysis attenuates Parkinson\u2019s disease progression in models and clinical databases. J Clin Investig. 2019;129(10):4539\u20134549.","journal-title":"J Clin Investig"},{"issue":"4","key":"939_CR112","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamaneurol.2020.5157","volume":"78","author":"JE Simmering","year":"2021","unstructured":"Simmering JE, Welsh MJ, Liu L, Narayanan NS, Potteg\u00e5rd A. Association of glycolysis-enhancing \u03b1-1 blockers with risk of developing Parkinson disease. JAMA Neurol. 2021;78(4):407\u2013413.","journal-title":"JAMA Neurol"},{"issue":"11","key":"939_CR113","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","volume":"11","author":"E Sidransky","year":"2012","unstructured":"Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012;11(11):986\u201398.","journal-title":"Lancet Neurol"},{"key":"939_CR114","doi-asserted-by":"crossref","unstructured":"Silveira CRA, MacKinley J, Coleman K, Li Z, Finger E, Bartha R, et al. Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: Protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol. 2019;19(1):20.","DOI":"10.1186\/s12883-019-1252-3"},{"key":"939_CR115","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","volume":"5","author":"M Grundman","year":"2019","unstructured":"Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, et al. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease. Alzheimer\u2019s Dement Transl Res Clin Interv. 2019;5:20\u201326.","journal-title":"Alzheimer\u2019s Dement Transl Res Clin Interv."},{"key":"939_CR116","doi-asserted-by":"crossref","unstructured":"Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer\u2019s disease modification. Alzheimer\u2019s Dement. 2021;17(8)1365\u20131382.","DOI":"10.1002\/alz.12302"},{"issue":"6","key":"939_CR117","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/cells8060565","volume":"8","author":"M-L Arotcarena","year":"2019","unstructured":"Arotcarena M-L, Teil M, Dehay B. Autophagy in synucleinopathy: the overwhelmed and defective machinery. Cells. 2019;8(6):565.","journal-title":"Cells"},{"issue":"4","key":"939_CR118","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/mds.27962","volume":"35","author":"AL Barth","year":"2020","unstructured":"Barth AL, Schneider JS, Johnston TH, Hill MP, Brotchie JM, Moskal JR, et al. NYX-458 improves cognitive performance in a primate Parkinson\u2019s disease model. Mov Disord. 2020;35(4):640\u20139.","journal-title":"Mov Disord"},{"key":"939_CR119","unstructured":"CuraSen. Safety, Tolerability and cerebral blood flow after single doses of the \u03922-agonist, Clebbuterol, in patients with mild cognitive impairment or Parkinson\u2019s disease. [Internet]. 2021 [cited 2022 Mar 30]. https:\/\/www.curasen.com\/curasen-therapeutics-presents-phase-1b-clinical-data-with-cst-103-demonstrating-significant-increases-in-cerebral-blood-flow-in-patients-with-mild-cognitive-impairment-or-parkinsons-disease\/."},{"key":"939_CR120","doi-asserted-by":"crossref","unstructured":"Lodeweyckx T, De hoon J, Van Laere K, Koole M, Vandenberghe W, Bishop C, et al. Abstract: Posters: 14th Clinical Trials on Alzheimer\u2019s Disease (CTAD) November 9-12, 2021. J Prev Alzheimer\u2019s Dis [Internet]. 2021;8(S1):S73\u2013170. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34773456","DOI":"10.14283\/jpad.2021.58"},{"key":"939_CR121","unstructured":"ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine, (US). A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders (CLIN-011) [Internet]. NCT04739423. 2021 [Accessed 2022 Dec 3]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04739423?term=cst-103&cond=Lewy+Body+Disease&draw=2&rank=1."},{"issue":"8","key":"939_CR122","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/sj.gt.3303094","volume":"15","author":"D Takeuchi","year":"2008","unstructured":"Takeuchi D, Sato N, Shimamura M, Kurinami H, Takeda S, Shinohara M, et al. Alleviation of A\u03b2-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 2008;15(8):561\u201371.","journal-title":"Gene Ther"},{"key":"939_CR123","unstructured":"Moebius H, Hua X, Church K, Walker W, L\u2019hostis P, Danjou P, et al. Phase 1 study of NDX-1017: safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and dementia patients. J Prev Alzheimer\u2019s Dis. 2019;6, S22."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00939-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-022-00939-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00939-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T11:49:45Z","timestamp":1675684185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-022-00939-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":123,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1007\/s40266-022-00939-w","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"25 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no funding\u00a0for this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Babak Tousi has received consultancy and speaker fees and been a consultant for Eisai, Biogen, and Lilly. He has received honorarium for the Scientific Advisory Board from Biogen, Eisai, and Lilly. Steve MacDonald and Ayushi Shah have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"BT and SM had the idea for the article, drafted and critically revised the work. BT, AS, and SM performed the literature search and data analysis. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}